Progress and opportunities in measuring the burden of Chronic Kidney Disease by Priya Vart, Hiddo J.L. Heerspink

Get full text

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice? by Paul Perco, Michelle Pena, Hiddo J.L. Heerspink, Gert Mayer

Get full text

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trial... by Willem Collier, Benjamin Haaland, Lesley A. Inker, Hiddo J.L. Heerspink, Tom Greene

Get full text

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers by Sok Cin Tye, Sieta T. de Vries, Christoph Wanner, Petra Denig, Hiddo J. L. Heerspink

Get full text

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores by Nienke M. A. Idzerda, Sok Cin Tye, Dick de Zeeuw, Hiddo J. L. Heerspink

Get full text

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives by Frederik F. Kreiner, Philip Andreas Schytz, Hiddo J. L. Heerspink, Bernt Johan von Scholten, Thomas Idorn

Get full text

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020 by Elisabeth Bakker, Viktoriia Starokozhko, Jet W. M. Kraaijvanger, Hiddo J. L. Heerspink, Peter G. M. Mol

Get full text

Indirect Insulin Resistance Indices and Their Cut-Off Values for the Prediction of Post-Transplantation Diabetes Mellitus in Kidney Transplant Recipients by Sara Sokooti, Tamás Szili-Török, Hiddo J. L. Heerspink, Robin P. F. Dullaart, Stephan J. L. Bakker

Get full text

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN... by Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen, Linda G. Mellbin

Get full text

Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study by Sara Sokooti, Jose L. Flores-Guerrero, Hiddo J. L. Heerspink, Margery A. Connelly, Stephan J. L. Bakker, Robin P. F. Dullaart

Get full text

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists by Michaël J. B. van Baar, Annemarie B. van der Aart, Klaas Hoogenberg, Jaap A. Joles, Hiddo J. L. Heerspink, Daniël H. van Raalte

Get full text

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure by Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink

Get full text

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial by Taha Sen, Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Wayne Shaw, William Canovatchel, Michael K. Hansen, Hiddo J. L. Heerspink

Get full text

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial by Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink

Get full text

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels by Christina M. Gant, Gozewijn D. Laverman, Liffert Vogt, Maartje C. J. Slagman, Hiddo J. L. Heerspink, Femke Waanders, Marc H. Hemmelder, Gerjan Navis, Holland Nephrology Study (HONEST) Network

Get full text

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe by Jeroen V. Koomen, Jeroen V. Koomen, Jasper Stevens, Margje H. Monster-Simons, Margje H. Monster-Simons, Hiddo J. L. Heerspink, Peter G. M. Mol, Peter G. M. Mol

Get full text

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers by Sok Cin Tye, Sieta T. de Vries, Johannes F. E. Mann, Johannes F. E. Mann, Meir Schechter, Meir Schechter, Ofri Mosenzon, Ofri Mosenzon, Petra Denig, Hiddo J. L. Heerspink

Get full text

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial by Reza Mohebi, Yuxi Liu, Michael K. Hansen, Yshai Yavin, Naveed Sattar, Carol A. Pollock, Javed Butler, Meg Jardine, Serge Masson, Hiddo J. L. Heerspink, James L. Januzzi Jr

Get full text

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... by Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

Get full text

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes by Sjoukje van der Hoek, Jeroen V. Koomen, Erik J. M. van Bommel, Charlotte M. Mosterd, Rosalie A. Scholtes, Anne C. Hesp, Jasper Stevens, Daniel H. van Raalte, Hiddo J. L. Heerspink

Get full text